Ernexa Therapeutics (ERNAW) Cash from Operations (2010 - 2026)
Ernexa Therapeutics' (ERNAW) quarterly Cash from Operations came in at 2264000.0 in Q1 2026, down 9.64% YoY from 2505444.8 in Q1 2025, and down 97.21% on a QoQ basis from 1148000.0 in Q4 2025.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Cash from Operations (2010 - 2026) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 17 years of Cash from Operations data on file, last reported at 2264000.0 in Q1 2026.
- Quarterly Cash from Operations fell 9.64% year-over-year to 2264000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7216000.0 (up 49.02% YoY) and the FY2025 annual result came in at 7017000.0, up 55.69% from the prior year.
- Cash from Operations slipped to 2264000.0 in Q1 2026, from 1148000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1148000.0 in Q4 2025 to a low of 6285000.0 in Q3 2024.
- A 5-year average of 3911823.53 and a median of 3872000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 58.37% — and 2025, when it jumped 79.81%.
- Tracing ERNAW's Cash from Operations over 5 years: stood at 5435000.0 in 2022, then grew by 14.24% to 4661000.0 in 2023, then climbed by 23.94% to 3545000.0 in 2024, then jumped by 67.62% to 1148000.0 in 2025, then tumbled by 97.21% to 2264000.0 in 2026.
- The last three Cash from Operations figures came in at 2264000.0 (Q1 2026), 1148000.0 (Q4 2025), and 1269000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - | -4.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.12 Mn |
| Mar 31, 2026 | -2.30 Mn |
| Dec 31, 2025 | -1.12 Mn |
| Sep 30, 2025 | -1.30 Mn |
| Jun 30, 2025 | -2.53 Mn |
| Mar 31, 2025 | -2.07 Mn |
| Dec 31, 2024 | -3.55 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Jun 30, 2024 | -2.26 Mn |
| Mar 31, 2024 | -3.75 Mn |
| Dec 31, 2023 | -4.66 Mn |
| Sep 30, 2023 | -5.83 Mn |
| Jun 30, 2023 | -3.87 Mn |
| Mar 31, 2023 | -6.05 Mn |
| Dec 31, 2022 | -5.44 Mn |
| Sep 30, 2022 | -6.12 Mn |
| Jun 30, 2022 | -3.99 Mn |
| Mar 31, 2022 | -5.43 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -6.42 Mn |